( February 3, 2026, 1:49 PM EST) -- WASHINGTON, D.C. — A Ninth Circuit U.S. Court of Appeals ruling that found no error in the certification of a national third-party payer (TPP) class of entities that paid for the diabetes drug Actos, despite the court recognizing that there is no way to calculate the number of class members that were not harmed, does not warrant review by the U.S. Supreme Court, Painters and Allied Trades District Council 82 Health Care Fund argues in an opposition filed Feb. 2....